Clinical activity of crizotinib in lung adenocarcinoma harboring a ‑ rearrangement: A case report.

The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 ()-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of -rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib.